Black Diamond faces treacherous terrain
To view this email as a web page, click here

Today's Rundown

Featured Story

Weeks after Sanofi flop, Roche's rival breast cancer drug flunks phase 2 test

Chalk up another setback to the oral SERDs. In the wake of data that sank Radius Health's stock and the failure of Sanofi’s prospect, Roche has revealed giredestrant missed the mark in a midphase breast cancer trial, raising doubts about the drug ahead of further data drops.

read more

Top Stories

Phase 2 deja vu for gossamer bio after ulcerative colitis med flops

Gossamer bio is headed back to the drawing board after its ulcerative colitis med flopped in phase 2, prompting the company to end open-label and treat-through extensions of the trial. The company did not specifically say whether or not it would continue with the program.

read more

Black Diamond runs into rocky terrain, trims 30% of workforce and cuts precision oncology program

Black Diamond Therapeutics is closing down at least one run at a precision oncology med after getting a glimpse of the rocky terrain ahead and cutting 30% of staff in the process.

read more

Sponsored: Using Knowledge Graphs to Drive Drug Discovery

Biomedical knowledge graphs can power many different application in drug discovery. Learn which key feature you should look for and why.

read more

Roche delays DMD drug deadline, decides to rejig MS trials because of Ukraine war

When it comes to clinical trials, things rarely go to plan. Just ask Roche, which revealed today that it has pushed back the regulatory timeline for its Duchenne muscular dystrophy (DMD) treatment by a year. In addition, the Big Pharma noted that the conflict in Ukraine has thrown its multiple sclerosis trials into disarray.

read more

Clean safety profiles and complete responses: Nkarta releases early-stage data for 2 cancer candidates

Following a blockbuster IPO and partnership with CRISPR, clinical-stage biotech Nkarta has released some of the first data for its two leading engineered natural killer (NK) cell programs to treat cancer.

read more

Reprogramming a new type of T cell to go after cancers with less side effects, longer impact

Immunotherapy is one of the more appealing and effective kinds of cancer treatment but is still fairly limited in the kinds of cancer it can be used for. Researchers at the Sloan Kettering Institute discovered the workings of a new kind of immune cell that could expand the reach of immunotherapy treatments to a much wider pool of patients.

read more

Toronto researchers say ‘double negative’, off-the-shelf CAR-T treatment could bolster cell therapy

A new study from a team of researchers in Toronto bolsters support for a novel "off-the-shelf" CAR-T treatment. The scientists found that "double negative" allogenic CAR-T cells were able to fight two types of cancers in a mouse model without the cells attacking the host's body.

read more

The top advertisers in Big Pharma

The pandemic had a major effect on how pharma spent its marketing cash: While spending on direct-to-consumer branded drug ads remained flat in 2021, unbranded campaigns went through the roof.

read more

Here's why some systems say they're comfortable relaxing hospital mask requirements

Houston Methodist and UnityPoint Health are among those letting staff and visitors cut back on masking outside clinical areas. With constant surveillance, they say the policy offers much-needed relief to staff members grappling with pandemic burnout.

read more

Ardelyx's Hail Mary caught, as FDA agrees on appeal to convene advisory committee for tenapanor

Ardelyx's Hail Mary attempt to save the FDA application for its kidney drug seems to have worked, as the agency has granted the struggling biotech a hearing for tenapanor.

read more

Roche drinks in COVID test sale gains but preps for the well to run dry

Omicron’s surge in January drove Roche’s diagnostics sales to new highs in the first quarter of this year, as high demand for rapid COVID-19 tests joined forces with the momentum in the division’s base businesses.

read more

Gilead touts analysis showing COVID antiviral Veklury performs best when given early in illness

During the European Congress of Clinical Microbiology & Infectious Diseases, Gilead Sciences presented data that showed its COVID-19 antiviral Veklury performs better the earlier it is provided in both patients with severe and mild-to-moderate cases of the virus.

read more

Resources

Research: Healthcare Has No Borders: The Role of Rescue Sites in Times of Global Calamity

More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play?

Infographic: United Cargo: Providing Comprehensive Solutions For the Most Critical Shipments

The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now.

Research: Get Access to AdisInsight A Year In Review

The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge).

Whitepaper: Oncology Market Outlook: Key Trends to Watch

What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market.

Whitepaper: Uncovering the hidden value of quality in chemical supply

Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific.

Events